Priming therapy biotech emerges from stealth with seed funding — and on a hunt for partners
At Eigen Therapeutics, the goal is to make cancer treatment more effective. But not by making targeted drugs.
With $7 million in seed funding announced today, Eigen is a step closer to developing what are known as “priming therapies” that make cancer cells more visible to tumor-killing medicines, as well as building out a platform to design these therapies and discover potential new drug classes.
It’s a two-step approach to treating cancer: The first step is the priming therapy, shining a figurative spotlight on cancer cells to make them more recognizable to targeted therapies. Then, such treatments can more easily find and attack the tumors and eliminate the cancer without doing as much damage to healthy cells.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.